Shots:

• Arcus will receive an option exercise fees along with an additional milestone upon achievement of clinical, regulatory, and commercialization milestones along with royalties on net sales of the products under an option and license agreement b/w Taiho and Arcus as reported in Sept 2017
• Taiho will be responsible for the development and commercialization of domvanalimab and will continue to deliver innovative drugs to patients and others
• Arcus is conducting the P-II (ARC-7) & P-III (ARC-10) trials of domvanalimab + zimberelimab as 1L treatment of metastatic PD-L1≥50% NSCLC while P-III (PACIFIC-8) trial of domvanalimab + durvalumab  is being initiated in Stage III NSCLC

Ref: Businesswire | Image: Taiho